We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





STAGO sthemO and sthemE Product Ranges Make World Premiere

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)

Diagnostica Stago (Asnières-sur-Seine, France) is unveiling its new coagulation line - the sthemO and sthemE product ranges - at WorldLab–EuroMedLab Roma 2023.

Leveraging its proficiency in hemostasis, Stago has diversified its product line to incorporate hematology, becoming a multi-specialist in these fields. The company's new "sthem" brand represents a significant leap towards next-generation Stago solutions. Drawing from over 60 years of partnership with coagulation professionals, Stago has introduced sthemO, a fresh line of hemostasis devices and reagents designed to fulfill the evolving demands of laboratories. The sthemO 301, the first analyzer in the sthemO hemostasis series, is a high-throughput, fully automated coagulation analyzer designed for medium to large laboratories and can be integrated into automated tracks. It offers the perfect combination of expertise, performance, and innovation. Also included in the new range of sthemO analyzers by Stago is the sthemO 201. This bench-top analyzer, suitable for smaller laboratories, offers the same level of efficiency and analytical performance as the sthemO 301. Its simplicity and versatility enable laboratories to concentrate on value-added tasks.

The sthemO analyzers are qualitative and/or quantitative automated hemostasis platforms for in vitro diagnostic use by clinical laboratory staff and are to be used with dedicated sthemO reagents and controls. The company has emphasized technological advancement, integrating an increasing number of features into its sthemO coagulation devices to simplify operations for laboratories and patients alike. The sthemO series incorporates immuno-chemiluminescence technology to provide superior analytical performance and an extensive range of tests. Additionally, Stago has developed a unique cuvette design, compatible with all embedded technologies, to provide a highly efficient, user-friendly system.

In order to optimize these two novel systems, Stago has also launched new eSolutions under the sthemE umbrella. The sthemE Manager is designed to facilitate data and information exchange between one or several in vitro diagnostic analyzers and laboratory information systems. This system, encompassing the sthemE Manager and one or more analyzers, is managed by authorized laboratory personnel. sthemE Manager is not intended for use with specific assays.

Related Links:
Diagnostica Stago

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.